Medicinal Chemistry Endeavors around the Phytocannabinoids

  title={Medicinal Chemistry Endeavors around the Phytocannabinoids},
  author={Eric W. Stern and Didier M. Lambert},
  journal={Chemistry \& Biodiversity},
Over the past 50 years, a considerable research in medicinal chemistry has been carried out around the natural constituents of Cannabis sativa L. Following the identification of Δ9‐tetrahydrocannabinol (Δ9‐THC) in 1964, critical chemical modifications, e.g., variation of the side chain at C(3) and the opening of the tricyclic scaffold, have led to the characterization of potent and cannabinoid receptor subtype‐selective ligands. Those ligands that demonstrate high affinity for the cannabinoid… 

Biological activity of Cannabis compounds: a modern approach to the therapy of multiple diseases

This review summarizes the current knowledge of selected active C. indica compounds and their therapeutic potential, including the main compounds contained in cannabis, the mechanisms of their effects, and their potential therapeutic applications.

Cannabis Phytochemicals: A Review of Phytocannabinoid Chemistry and Bioactivity as Neuroprotective Agents

Emergent evidence is outlined for the potential for selected phytocannabinoids and other cannabis phytochemicals to mitigate factors such as inflammation and oxidative stress as drivers of neurotoxicity, in addition to focusing on specific interactions with pathological misfolding proteins associated with major forms of neurodegenerative diseases such as Alzheimer’s disease.

Naturally occurring and related synthetic cannabinoids and their potential therapeutic applications.

This article reviews patents (2003-2007) that describe methods for isolation of cannabinoids from cannabis, chemical and chromatographic methods for their purification, synthesis, and potential therapeutic applications of these compounds.

Phytocannabinoids: General Aspects and Pharmacological Potential in Neurodegenerative Diseases

This review aims to present a state of art in the research with cannabinoids and novel cannabinoid-based drug candidates that have been emerged as novel promising alternatives for drug development and innovation in the therapeutics of a number of diseases, especially those related to CNS-disturbance and impairment.

Structure-Activity Relationship of Cannabis Derived Compounds for the Treatment of Neuronal Activity-Related Diseases

This review will consider the structure-activity relationship (SAR) of cannabinoid compounds able to bind to cannabinoid receptors and act as therapeutic agents in neuronal diseases, e.g., Parkinson’s disease.

Phytocannabinoids: a unified critical inventory.

The integrated inventory of these compounds and their biological macromolecular end-points highlights the opportunities that phytocannabinoids offer to access desirable drug-like space beyond the one associated to the narcotic target CB1.

A Contribution to the Synthesis of Cannabinoids

Improvements herein are applicable to the synthesis of classical, non-classical, and hybrid cannabinoid classes, and have been demonstrated through the total synthesis of enantioenriched nabilone — a highly potent cannabinoid ligand in its own right, and whose racemate is a FDA approved pharmaceutical ingredient and arguably the most iconic ketocannabinoid.



Synthesis and antitumor activity of quinonoid derivatives of cannabinoids.

Three cannabis constituents, cannabidiol (1), Delta(8)-tetrahydrocannabinol (3), and cannabinol (5), were oxidized to their respective para-quinones 2, 4, and 6, and quinone 2 significantly reduced cancer growth of HT-29 cancer in nude mice.

Selective and Potent Analgetics Derived from Cannabinoids

Modifications of the side chain, the phenolic moiety, and structures that lack the benzopyran functionality present in THC and HHC are examined, resulting in a unique family of benzoquinolines with potent analgetic activity.

Synthesis and pharmacology of a hybrid cannabinoid.

Pharmacophoric requirements for the cannabinoid side chain. Probing the cannabinoid receptor subsite at C1'.

The existence and stereochemical features of a subsite within the CB1 and CB2 cannabinoid receptor binding domain corresponding to substituents at the benzylic side chain position of classical cannabinoids are probed through the synthesis of a novel series of (-)-Delta(8)-tetrahydrocannabinol analogues bearing C1'-ring substituent.

Adamantyl cannabinoids: a novel class of cannabinergic ligands.

The results suggest that although a bulky group at the C3 position of classical cannabinoids could be tolerated by both CB1 and CB2 binding sites, the relative orientation of that group with respect to the tricyclic component can lead to receptor subtype selectivity.

Pharmacological evaluation of iodo and nitro analogs of Δ 8-THC and Δ 9-THC

New cannabidiol derivatives: synthesis, binding to cannabinoid receptor, and evaluation of their antiinflammatory activity.

Surprisingly, it is found that hydrogenated CBD and CBD-DMH exhibit good binding to the cannabinoid receptor (CB(1), and demonstrate bioactivities different from their original compounds.

Molecular characterization of a peripheral receptor for cannabinoids

The cloning of a receptor for cannabinoids is reported that is not expressed in the brain but rather in macrophages in the marginal zone of spleen, which helps clarify the non-psychoactive effects of cannabinoids.


The main conclusion reached was that the side chain on the aromatic ring was of considerable importance and the introduction into clinical practice in the late 40s of the CsHI3 homolog of AS-THC (synhexyl) was the most active compound reported.

Manipulation of the tetrahydrocannabinol side chain delineates agonists, partial agonists, and antagonists.

The finding that manipulations of the side chain produces high- affinity ligands with either antagonist, partial agonist, or full agonist effects reveals a critical structural feature for receptor activation.